Adenoviral gene transfer of nitric oxide synthase: High level expression in human vascular cells

Cardiovascular Research

Volumn 32, Issue 5, 1996, Pages 962-972

  Channon, Keith M ^a   Blazing, Michael A ^a   Shetty, Geetha A ^a   Potts, Kevin E ^a   George, Samuel E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

gene expression; gene therapy; gene transfer, adenovirus; human, smooth muscle cell; human, umbilical vein endothelial cell (HUVEC); nitric oxide

Indexed keywords

ACETYLCHOLINE; BRADYKININ; CALCIUM IONOPHORE; NITRIC OXIDE SYNTHASE;

ADENOVIRUS; ARTICLE; CONTROLLED STUDY; GENE THERAPY; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VIRUS CARRIER;

ADENOVIRIDAE; BLOTTING, WESTERN; CELLS, CULTURED; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; ISOENZYMES; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; UMBILICAL VEINS;

EID: 0030296392     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00125-3     Document Type: Article

References (41)

1. [1] Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Topics Microbiol Immunol 1992;158:39-66.
2. [2] Kozarsky KF, Wilson JM. Gene therapy: Adenovirus vectors. Curr Opin Genet Dev 1993;3:499-503.
3. [3] Nabel EG. Gene therapy for cardiovascular disease. Circulation 1995;91:541-548.
4. [4] Channon KM, Blazing MA, George SE. Vascular gene transfer. Heart 1996;85:215-217.
5. [5] Willard JE, Landau C, Glamann DB, et al. Genetic modification of the vessel wall: Comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation 1994;89:2190-2197.
6. [6] French BA, Mazur W, Geske RS, Bolli R. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 1994;90:2414-2424.
7. [7] Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation 1995;91:2407-2414.
8. [8] Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993;90:2812-2816.
9. [9] Ohno T, Gordon D, San H, Pompili VJ, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-784.
10. [10] Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-522.
11. [11] Muhlhauser J, Pili R, Merrill MJ, et al. In vivo angiogenesis induced by recombinant adenovinis vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor. Human Gene Therapy 1995;6:1457-1465.
12. [12] Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994;78:927-930.
13. [13] Griffith OW, Stuehr DJ. Nitric oxide synthases: Properties and catalytic mechanism. Annu Rev Physiol 1995;57:707-736.
14. [14] Wang J, Stuehr DJ, Rousseau DL. Tetrahydrobiopterin-deficient nitric oxide synthase has a modified heme environment and forms a cytochrome P-420 analogue. Biochemistry 1995;34:7080-7087.
15. [15] Cho HJ, Martin E, Xie QW, Sassa S, Nathan C. Inducible nitric oxide synthase - identification of amino acid residues essential for dimerization and binding of tetrahydrobiopterin. Proc Natl Acad Sci USA 1995;92:11514-11518.
16. [16] Schmidt HHHW, Walter U. NO at work. Cell 1994;78:919-925.
17. [17] Knowles RG, Moncada S. Nitric oxide as a signal in blood vessels. Trends Biochem Sci 1992;17:399-402.
18. [18] Dinerman JL, Lowenstein CJ, Snyder SH. Molecular mechanisms of nitric oxide regulation: potential relevance to cardiovascular disease. Circ Res 1993;73:217-222.
19. [19] Lüscher TF, Tanner FC, Tschudi MR, Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med 1993;44:395-418.
20. [20] Radomski MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;148:1482-1489.
21. [21] Simon DI, Stamler JS, Jaraki O, Keaney JF, Osborne JA, Francis SA, et al. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 1993;13:791-799.
22. [22] Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
23. [23] Nunokawa Y, Tanaka S. Interferon-gamma inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem Biophys Res Commun 1992;188:409-415.
24. [24] Von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-1141.
25. [25] Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 1979;17:683-689.
26. [26] Friedman JM, Babiss LE, Clayton DF, Darnell JE. Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression. Mol Cell Biol 1986;6:3791-3797.
27. [27] Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991;351:714-718.
28. 15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138.
29. [29] Graham FL, Prevec L. Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols. Clifton, NJ: Humana Press, 1991;109-128.
30. [30] Gross SS, Levi R. Tetrahydrobiopterin synthesis: an absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 1992;267:25722-25729.
31. 2+-dependent nitric oxide synthase in bovine aortic endothelial cells. Am J Physiol Cell Physiol 1995;38:C 757-C 765.
32. [32] Dawson TM, Bredt DS, Fotuhi M, Hwang PM, Snyder SH. Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci USA 1991;88:7797-7801.
33. [33] Bredt DS, Ferris CD, Snyder SH. Nitric oxide synthase regulatory sites: phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin dependent protein kinase; identification of flavin and calmodulin binding sites. J Biol Chem 1992;267:10976-10981.
34. [34] Lemarchand P, Jaffe HA, Danel C, et al. Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA 1992;89:6482-6486.
35. [35] Bredt D.S, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87:682-685.
36. [36] Shepherd JT, Katusic ZS. Endothelium-derived vasoactive factors: I, endothelium-dependent relaxation. Hypertension 1991;18(suppl. III):III-76-III-85.
37. [37] Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993;73:797-807.
38. [38] Steg PG, Feldman LJ, Scoazec J-Y, Tahlili O, Barry JJ, Boulechfar S, et al. Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. Circulation 1994;90:1648-1656.
39. [39] Scott-Burden T. Regulation of nitric oxide production by tetrahydrobiopterin. Circulation 1995;91:248-250.
40. [40] Harrison DG. Alterations of vasomotor regulation in atherosclerosis. Cardiovasc Drugs Ther 1995;9 Suppl. 1:55-63.
41. [41] Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 1995;38:105-128.